ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nomori, H.
Right arrow Articles by Suemasu, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nomori, H.
Right arrow Articles by Suemasu, K.
Related Collections
Right arrowRelated Article

Ann Thorac Surg 2000;70:1803-1807
© 2000 The Society of Thoracic Surgeons


Original article: general thoracic

Double stenting for esophageal and tracheobronchial stenoses

Hiroaki Nomori, MDa, Hirotoshi Horio, MDa, Yoshihiro Imazu, MDa, Keiichi Suemasu, MDa

a Department of Thoracic Surgery, Saiseikai Central Hospital, Tokyo, Japan

Accepted for publication May 14, 2000.

Address reprint requests to Dr Nomori, Department of Surgery, Saiseikai Central Hospital, 1-4-17 Mita, Minato-ku, Tokyo 108-0073, Japan
e-mail: hnomori{at}qk9.su-net.ne.jp


    Abstract
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
Background. We examined the complications and outcomes of placing stents for both esophageal and tracheobronchial stenoses.

Methods. We placed stents for both esophageal and tracheobronchial stenoses in 8 patients (7 with esophageal cancer and 1 with lung cancer). Covered or noncovered metallic stents were used for the esophageal stenoses, except in 1 patient treated with a silicone stent. Silicone stents were used for the tracheobronchial stenoses. The grades of esophageal and tracheobronchial stenoses were scored.

Results. All patients experienced improvement of grades of both dysphagia and respiratory symptoms after stent therapy. The complications were: (1) 2 patients suffered respiratory distress after placement of the esophageal stent because of compression of the trachea by the stent; and (2) 3 patients developed new esophagotracheobronchial fistulae, and 2 patients had recurring fistula symptoms because of growth of preexisting fistulae after the stent placement, which were caused by pressure from the 2 stents. Despite the fistulae, the 5 patients treated with covered metallic stents did not complain of fistula symptoms, but 2 patients treated with noncovered metallic or silicone stents did complain.

Conclusions. For patients with both esophageal and tracheobronchial stenoses, a stent should be introduced into the tracheobronchus first. Because placement of stents in both the esophagus and tracheobronchus has a high risk of enlargement of the fistula, a covered metallic stent is preferable for esophageal cancer involving the tracheobronchus.


    Introduction
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
Recent advances in stent therapy have increased the quality of life of patients with inoperable cancer. Tracheobronchial stenoses have been treated by expandable metallic stent [1, 2] and silicone stent such as Dumon or dynamic stents [35]. Esophageal stenoses have classically been treated with plastic or silicone stent, but self-expandable metallic stent have recently been introduced for this purpose [5, 6]. Patients with advanced esophageal cancer often have respiratory distress as a result of tracheobronchial invasion, and this necessitates stent therapy not only for esophageal stenosis but also for tracheobronchial stenosis. In this report we examine the outcomes of stent therapy for both esophageal and tracheobronchial stenoses in 8 patients and recommend some management techniques that can be used to prevent complications.


    Material and methods
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
From 1991 to 1999, we performed stent therapy for 28 patients with esophageal stenoses and 45 patients with tracheobronchial stenoses. Of these, 8 patients received stent therapy for both esophageal and tracheobronchial stenoses (Table 1). The causes of the stenoses were esophageal cancer in 7 patients and lung cancer in 1. The mean length of esophageal stenoses in the esophageal cancer patients was 5.7 cm (range: 3–9). The sites of airway stenoses were the trachea in 5 patients, the left main bronchus in 2, and the right main bronchus in 1. All patients underwent chemoradiotherapy before the stent placements. In addition, one patient (patient 1) underwent also radiotherapy after the stent placement. Four patients (patient 5, 6, 7 and 8) already had fistulae before stent therapy. For tracheobronchial stenosis, we used silicone stents but not metallic stents to prevent a recurrence of stenosis due to tumor growth between the wires of the metallic stents [2]. Six Dumon stents (Novatech Co, Aubagne, France) were placed in 6 patients and 2 dynamic stents (Willy Rüsch AG, Kernen, Germany) in 2. Dumon stents were placed via an endotracheal tube under general anesthesia as described previously [4]. The dynamic stents were placed using specialized forceps under general anesthesia. The esophageal metallic stents were placed using the regular method under local anesthesia [57]. For esophageal stenosis, we generally used metallic stents but not silicone stents, because silicone stents tend to have a higher risk of esophageal injury and are also easily packed with food. Nine covered self-expandable metallic stents (Covered Ultraflex Esophageal Stent System, Microinvasive, Boston Scientific Co, Boston, MA) were placed in 6 patients, 2 noncovered Ultraflex metallic stents in 2 patients, and 1 silicone stent (Flexible Artificial Esophagus, Sumitomo Bakelite Co, Ltd, Tokyo, Japan) in 1.


View this table:
[in this window]
[in a new window]
 
Table 1. Patients Characteristics and Treatments for Esophageal and Airway Stenosis

 
The main purposes for using these esophageal stents were to dilate the stenoses in 6 patients (patients 1, 2, 3, 4, 6 and 8) and to block the esophagotracheobronchial fistula in the 2 (patients 5 and 7). A noncovered metallic stent or a silicone stent had to be used in 2 patients (patients 1 and 2) because a covered metallic stent was not commercially available in Japan at the time of treatment.

In 5 patients (patients 1, 2, 3, 4 and 5), we placed the esophageal stent first, followed by the tracheobronchial stent, because the symptoms of esophageal stenosis or fistula were more conspicuous than those of airway stenosis. In the remaining 3 patients (patients 6, 7 and 8), who had both esophageal and tracheobronchial stenoses before the stent therapy, we placed the tracheobronchial stents first, followed by the esophageal stents, because, if the esophageal stents had been placed first, we would have risked deterioration of the tracheobronchial stenoses from compression by the esophageal stent. All patients except one (patient 7) underwent two-staged stent placements. Patient 7 underwent the placement of an airway stent followed by an esophageal stent on the same day. The mean periods between the diagnosis of the disease and stent placements were 9 months (range, from 2–20 months) for the airway stents and 6 months (range, from 0–18 months) for the esophageal stents.

To assess the results of stent therapy, we classified tracheobronchial stenosis into 4 grades as follows: grade 0, few complaints; grade 1, medium-grade stenosis; grade 2, high-grade stenosis without cyanosis; and grade 3, subtotal stenosis with cyanosis. Esophageal stenoses were classified into 4 grades as follows: grade 0, a patient can consume any kind of food; grade 1, a patient can consume soft foods without the nutritional support; grade 2, a patient can consume liquid food without the nutritional support; and grade 3, a patient needs some nutritional supports by either tube feeding or intravenous hyperalimentation because of an insufficient oral intake.


    Results
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
Immediate improvement of grades of both respiratory symptoms and dysphagia was achieved in all patients after stent placements (Table 2). The symptoms of tracheobronchial stenoses did not recur in any of our cases until the patients’ death. The symptoms of esophagotracheobronchial fistulae also improved after the placement of esophageal covered metallic stent. The mean period of taking meals without the nutritional support after esophageal stent placements was 5 months (range, from 2–16 months). The major complications were: (1) respiratory distress in 2 patients because of severe tracheal stenosis from compression by a single esophageal stent; (2) occurrence of a fistulae after double-stent placement in 2 patients; (3) occurrence of a fistula at the time of placement of a Dumon stent in 1 patient; and (4) recurrence of fistula symptoms due to growth of fistula after double-stent placement in 2 patients. In the next, we present these complications in detail.


View this table:
[in this window]
[in a new window]
 
Table 2. Results of Stenting After Esophageal and Tracheobronchial Stenoses

 
Patients 1 and 2 (see Table 1) had both esophageal and tracheal stenoses before the stent therapy, but no respiratory symptoms (Fig 1). They complained of severe dyspnea immediately after the placement of their esophageal stents: these symptoms were caused by deterioration of the tracheal stenosis related to compression by the esophageal stent. We therefore removed their esophageal stents promptly, resulting in immediate relief of symptoms in both patients. We then placed tracheal stents followed by another esophageal stents.



View larger version (62K):
[in this window]
[in a new window]
 
Fig 1. CT showing stenoses of both the esophagus and trachea.

 
Patients 1 and 2 suffered new esophagotracheal fistulae at the collateral to the stent 5 and 4 weeks, respectively, after placement of the esophageal and tracheal stents (Figs 2A and B). Because a noncovered metallic stent or silicone stents were used in the esophagus in these patients, they complained of fistula symptoms. Because covered metallic stents were not commercially available at the time of treatment, we managed these patients by stopping oral feeding and switching to tube feeding or intravenous hyperalimentation.



View larger version (68K):
[in this window]
[in a new window]
 
Fig 2. (A) CT showing an esophagotracheal fistula beside the stents (arrow). (B) Chest X-ray showing a silicone stent in the esophagus (arrows) and a dynamic stent in the trachea.

 
Patient 4 suffered an esophagotracheal fistula at the time of Dumon-stent placement because of its procedure. He had received a covered metallic stent for esophageal cancer 2 months previously. The patient, however, did not complain of fistula symptoms, as the fistula was blocked by the covered metallic stent that had been previously placed in the esophagus (Fig 3).



View larger version (131K):
[in this window]
[in a new window]
 
Fig 3. Dumon stent and covered metallic stent placed in the trachea and esophagus, respectively.

 
Patients 5 and 7 had recurring symptoms of fistulae 1 and 10 weeks, respectively, after the placement of stents in both the esophagus and tracheobronchus. These recurring symptoms were caused by growth of the pre-existing fistulae: pressure from both the stents caused extensive necrosis of the esophageal and tracheobronchial walls. Placement of additional esophageal covered metallic stents improved the fistula symptoms in both patients, who became able to take a meal without nutritional support.

Seven patients died of their tumors from 38 to 96 days (mean: 72 days) after placement of the stents in both the esophagus and tracheobronchus. Patient 6 died of massive bleeding from the tumor 76 days after the double stenting. The remaining patient is now still alive 211 days after the double stenting without dysphagia or dyspnea.


    Comment
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 
Although our study showed that double stenting for esophageal and tracheobronchial stenoses effectively relieved symptoms, we discovered 2 main complications: (1) in patients with both esophageal and tracheal stenoses, the tracheal stenoses can deteriorate if they are compressed by the esophageal stents; and (2) with double stents, there is a high risk of fistula occurring or growing because of necrosis of both the esophageal and tracheobronchial walls from the pressure of the stents.

Two of our patients suffered the first complication, that is, deterioration of tracheal stenosis because of compression by the esophageal stent. They had both esophageal and tracheal stenoses, but did not complain of respiratory symptoms before placement of the esophageal stent. Placement of the esophageal stents compressed the trachea, resulting in severe tracheal stenosis and necessitating prompt removal of the esophageal stents. There have been no reports regarding this complication, but we recommend that: (1) tracheal stenoses should be examined by CT and bronchoscopy before placement of esophageal stents; and (2) for patients with both the esophageal and tracheal stenoses, the tracheal stent should be placed before the esophageal stent even if the patients does not have respiratory symptoms.

Five of our patients suffered the second complication listed above, that is, development or growth of esophagotracheobronchial fistulae after placement of both the esophageal and tracheobronchial stents. Of these, 4 patients underwent esophageal stent placement first and the remaining 1 underwent the tracheobronchial stent placement first. None of the patients suffered development or growth of fistulae during single-stent placement in the esophagus or tracheobronchus: these problems occurred after double stenting. In all the patients except 1, we used self-expandable metallic stents for esophageal stenoses, which gradually expand to its final outer diameter of 22 mm after placement, without extensive compression to the esophageal wall [6, 7]. Although the Dumon stent and dynamic stent are more rigid than the self-expandable metallic stent, their diameters are selected to match the lumen of tracheobronchus, avoiding excessive compression of the tracheobronchial wall. However, the pressure from both the stents placed at the esophagus and tracheobronchus can cause extensive necrosis of the walls, leading to the development or growth of fistulae. For esophageal cancer with fistula but with little tracheobronchial stenosis, we therefore recommend that only a covered metallic stent should be placed into the esophagus at first to block the fistula, whereas additional tracheobronchial stents should not be used to prevent the growth of the fistula as long as the tracheobronchial stenosis does not become more severe.

Maier and associates reported that 4 of 11 patients (36.3%) suffered esophageal rupture during single-stent placement for esophagus, and their patients had undergone excessive endoluminal pretreatment, such as photodynamic therapy followed by endoluminal high-dose brachyradiotherapy, before stent therapy, making the esophageal wall prone to be ruptured [8]. Our patients underwent chemoradiotherapy before stent therapy, but they did not receive locally excessive endoluminal treatment such as the Maier’s method, which could be a cause of no problems for fistula occurring or growing during single-stent placement in the present study.

We recommend the use of a covered metallic stent in esophageal cancer invading the tracheobronchus, even for patients without esophagotracheobronchial fistulae, because there is a high risk of fistula occurring in the future, especially if double stents need to be placed. Three of our patients (patients 4, 6 and 8) did not complain of fistula symptoms despite having fistulae, because they had been pretreated with covered metallic stents. Because a covered metallic stent can prevent or minimize fistula symptoms [9, 10], it is the treatment of choice for esophageal cancer invading the tracheobronchus, even for patients without fistulae.

In conclusion, although the placement of stents in both the esophagus and tracheobronchus can effectively relieve symptoms of dysphagia and airway stenosis, it should be kept in mind that: (1) for patients with both the esophageal and tracheobronchial stenoses, the tracheobronchial stent should be placed first to prevent worsening of the airway stenosis from compression by the esophageal stent; and (2) a covered metallic stent should be used for esophageal tumors involving tracheobronchus even for patients without the fistulae, because the double stents increases the risk of development or growth of esophagotracheobronchial fistulae.


    References
 Top
 Abstract
 Introduction
 Material and methods
 Results
 Comment
 References
 

  1. Wallace M.J., Charnsangavej D., Ogawa K., Carrasco C.H., Wright K.C., McKenna R., McMurtrey M., Gianturco C. Tracheobronchial tree: expandable metallic stents used in experimental and clinical applications. Work in progress. Radiology 1986;158:309-312.[Abstract/Free Full Text]
  2. Nomori H., Kobayashi R., Kodera K., Morinaga S., Ogawa K. Indications for an expandable metallic stent for tracheobronchial stenosis. Ann Thorac Surg 1993;56:1324-1328.[Abstract]
  3. Dumon J.F. A dedicated tracheobronchial stent. Chest 1990;97:328-332.[Abstract/Free Full Text]
  4. Nomori H., Horio H., Suemasu K. Dumon stent placement via endotracheal tube. Chest 1999;115:582-583.[Abstract/Free Full Text]
  5. Freitag L., Eicker R., Linz B., Greschuchna D. Theoretical and experimental basis for the development of a dynamic airway stent. Eur Respir J 1994;7:2038-2045.[Abstract]
  6. Ell C., Hochberger J., May A., Fleig W.E., Hahn E.G. Coated and uncoated self-expanding metal stents for malignant stenosis in the upper GI tract: preliminary clinical experiences with wall stents. Am J Gastroenterol 1994;89:1496-1500.[Medline]
  7. Knyrim K., Wanger H.J., Bethge N., Keymling M., Vakil N. A controlled trial of an expansible metal stent for palliation of esophageal obstruction due to inoperable cancer. N Engl J Med 1993;329:1302-1307.[Abstract/Free Full Text]
  8. Maier A., Pinter H., Friehs G.B., Renner H., Smolle-Jüttner F.M. Self-expandable coated stent after intraluminal treatment of esophageal cancer: a risky procedure?. Ann Thorac Surg 1999;67:781-784.[Abstract/Free Full Text]
  9. Wong K., Goldstraw P. Role of covered esophageal stents in malignant esophagorespiratory fistula. Ann Thorac Surg 1995;60:199-200.[Abstract/Free Full Text]
  10. Wu W.C., Katon R.M., Saxon R.R., Barton R.E., Uchida B.T., Keller F.S., Rosch J. Silicone-covered self expanding metallic stents for the palliation of malignant esophageal obstruction and esophagorespiratory fistulas: experience in 32 patients and a review of the literature. Gastrointest Endosc 1994;40:22-33.[Medline]

Related Article

Invited commentary
Mark K. Ferguson
Ann. Thorac. Surg. 2000 70: 1807. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
ChestHome page
H. Dutau, B. Toutblanc, C. Lamb, and L. Seijo
Use of the Dumon Y-stent in the Management of Malignant Disease Involving the Carina: A Retrospective Review of 86 Patients
Chest, September 1, 2004; 126(3): 951 - 958.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
J. H. Shin, H.-Y. Song, G.-Y. Ko, J.-O. Lim, H.-K. Yoon, and K.-B. Sung
Esophagorespiratory Fistula: Long-term Results of Palliative Treatment with Covered Expandable Metallic Stents in 61 Patients
Radiology, July 1, 2004; 232(1): 252 - 259.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M.P. Di Simone, S. Mattioli, F. D'Ovidio, and F. Bassi
Three-dimensional CT imaging and virtual endoscopy for the placement of self-expandable stents in oesophageal and tracheobronchial neoplastic stenoses
Eur. J. Cardiothorac. Surg., January 1, 2003; 23(1): 106 - 108.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
K. Miwa, M. Mitsuoka, K. Tayama, N. Tomita, S. Takamori, A. Hayashi, and K. Shirouzu
Successful Airway Stenting Using Silicone Prosthesis for Esophagobronchial Fistula
Chest, October 1, 2002; 122(4): 1485 - 1487.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
B. P. Madden, S. Datta, and N. Charokopos
Experience with ultraflex expandable metallic stents in the management of endobronchial pathology
Ann. Thorac. Surg., March 1, 2002; 73(3): 938 - 944.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
K. Miwa, T. Matsuo, S. Takamori, S. Sueyoshi, M. Mitsuoka, H. Fujita, A. Hayashi, and K. Shirouzu
Temporary Stenting for Malignant Tracheal Stenosis due to Esophageal Cancer: a Case Report
Jpn. J. Clin. Oncol., January 1, 2002; 32(1): 27 - 29.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nomori, H.
Right arrow Articles by Suemasu, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nomori, H.
Right arrow Articles by Suemasu, K.
Related Collections
Right arrowRelated Article


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS